{"prompt": "['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '6.3.2.', 'Activity', 'Participants should abstain from strenuous exercise for 24 hours before each blood', 'collection for clinical laboratory tests.', '6.4.', 'Screen Failures', 'Screen failures are defined as participants who consent to participate in the clinical study', 'but are not subsequently randomized in the study. A minimal set of screen failure', 'information is required to ensure transparent reporting of screen failure participants to', 'meet the Consolidated Standards of Reporting Trials (CONSORT) publishing', 'requirements and to respond to queries from regulatory authorities. Minimal information', 'includes demography, screen failure details, eligibility criteria and any serious adverse', 'events (SAEs).', 'Individuals who do not meet the criteria for participation in this study (screen failure)', 'may not be rescreened unless discussed with the medical monitor.', '7.', 'TREATMENTS', 'Study treatment is defined as any investigational treatment(s), marketed product(s),', 'placebo, or medical device(s) intended to be administered to a study participant according', 'to the study protocol.', '27']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', '7.1.', 'Treatments Administered', 'Study Treatment Name:', 'Danirixin', 'Placebo', '(GSK1325756H, the', 'hydrobromide', 'hemihydrate salt)', 'Dosage formulation:', 'White Film coated', 'White Film coated', 'tablets (oval shaped).', 'tablets (oval shaped).', 'Refer to', \"Refer to Investigator's\", 'Brochure for', \"Investigator's\", 'Brochure for', 'presentation and', 'presentation and', 'excipients', 'excipients', 'Unit dose strength(s)/Dosage level(s):', '35mg tablets (of free', 'N/A', 'base equivalent)', 'Route of Administration', 'Oral', 'Oral', 'Dosing instructions:', 'One tablet to be', 'One tablet to be taken', 'taken twice daily', 'twice daily with food', 'with food', 'Packaging and Labeling', 'Study Treatment will', 'Study Treatment will', 'be provided in a', 'be provided in a HDPE', 'HDPE bottle with', 'bottle with desiccant.', 'desiccant. Each', 'Each bottle will be', 'bottle will be labeled', 'labeled as required per', 'as required per', 'country requirement.', 'country requirement.', 'Manufacturer', 'GSK', 'GSK', '7.1.1.', 'Medical Devices', 'Subject to availability and any local restrictions on use, MDI sensor devices', '(manufactured by and purchased from Propeller Health) are being provided by GSK for', 'this study. These devices are fitted onto rescue medication MDI devices to electronically', 'record rescue medication usage. The MDI sensor devices have US FDA 510(k) clearance', 'to market (Class II medical device) and European Union CE marking (Class I medical', 'device).', 'Additional descriptive information and instructions for the eMDI monitoring devices are', 'provided in the SRM.', '28']['2016N293064_0', 'CONFIDENTIAL', '2018N394263_00', '205864', 'GSK medical device incidents, including those resulting from malfunctions of the device,', 'must be detected, documented, and reported by the Investigator throughout the study (see', 'Section 9.2).', '7.2.', 'Dose Modification', 'No individual participant dose modifications or adjustments are allowed.', '7.3.', 'Method of Treatment Assignment', 'This study will use an Interactive Web Response System (IWRS). All', 'participants will be centrally randomized using the IWRS. Before the study is', 'initiated, the log in information and directions for the IWRS will be provided to', 'each site.', 'Participant randomization will be stratified by smoking status (i.e. current', 'smoker or former smoker).', 'Study treatment will be dispensed to participants at the study visits summarized', 'in the SOA.', 'Returned study treatment should not be re-dispensed to any participant.', '7.4.', 'Blinding', 'This will be a double-blind study. Study participants, all study site staff, and all members', 'of the GSK study team will be blinded to individual participant treatment assignment.', \"A participant will be withdrawn if the participant's treatment code is unblinded by the\", 'investigator or treating physician. The primary reason for discontinuation (the event or', 'condition which led to the unblinding) will be recorded in the CRF.', \"GSK's Global Clinical Safety and Pharmacovigilance (GCSP) staff may unblind the\", 'treatment assignment for any participant with an SAE. If the SAE requires that an', 'expedited regulatory report be sent to one or more regulatory agencies, a copy of the', \"report, identifying the participant's treatment assignment, may be sent to investigators in\", 'accordance with local regulations and/or GSK policy.', '7.5.', 'Preparation/Handling/Storage/Accountability', 'The investigator or designee must confirm and document appropriate temperature', 'conditions have been maintained during transit for all study treatment received', 'and any discrepancies are reported and resolved before use of the study treatment.', 'Only participants enrolled in the study may receive study treatment and only', 'authorized site staff may supply or administer study treatment. All study', 'treatments must be stored in a secure, environmentally controlled, and monitored', '29']\n\n###\n\n", "completion": "END"}